GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (NAS:ACET) » Definitions » Cash from Discontinued Operating Activities

Adicet Bio (Adicet Bio) Cash from Discontinued Operating Activities : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Cash from Discontinued Operating Activities?

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Adicet Bio's Cash from Discontinued Operating Activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Adicet Bio received $0.00 Mil from discontinued investing activities. Adicet Bio's Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Adicet Bio Cash from Discontinued Operating Activities Historical Data

The historical data trend for Adicet Bio's Cash from Discontinued Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Cash from Discontinued Operating Activities Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash from Discontinued Operating Activities
Get a 7-Day Free Trial - - - - -

Adicet Bio Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash from Discontinued Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adicet Bio Cash from Discontinued Operating Activities Calculation

Cash from Discontinued Operating Activities is net cash from all of the entity's discontinued operating activities.

Cash from Discontinued Operating Activities for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Adicet Bio Cash from Discontinued Operating Activities Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Cash from Discontinued Operating Activities provided by GuruFocus.com. Please click on the following links to see related term pages.

Adicet Bio (Adicet Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (NAS:ACET) » Definitions » Cash from Discontinued Operating Activities
Comparable Companies
TSBX IOBT ADCT ANEB HCWB ATHA KZR XLO ELTX VANI OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
1IJA:Germany 1IJA:Germany
Address
200 Clarendon Street, Floor 6, Boston, MA, USA, 02116
Website
https://www.adicetbio.com
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.
Executives
Chen Schor director, officer: See Remarks PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Katie Peng director C/O ADICET BIO, INC., 200 BERKELEY STREET, 19TH FLOOR, BOSTON MA 02116
Steve Dubin director
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Don Healey officer: Chief Technology Officer 2635 TECHNOLOGY FOREST BOULEVARD, THE WOODLANDS TX 77381
Blake Aftab officer: Chief Scientific Officer C/O ADICET BIO, INC., 200 CLARENDON STREET, FLOOR 6, BOSTON MA 02116
Francesco Galimi officer: Chief Medical Officer 12930 VIA ESPERIA, DEL MAR CA 92014
Aya Jakobovits director 3135 HUTTON DRIVE, BEVERLY HILLS CA 90210
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Andrew Sinclair director C/O SOLENO THERAPEUTICS INC., 1235 RADIO ROAD, SUITE 110, REDWOOD CITY CA 94065
Michael Kauffman director C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Bastiano Sanna director C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Orbimed Capital Gp V Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carrie Krehlik officer: Chief Human Resources Officer 6015 COLTON BLVD, OAKLAND CA 94611